Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CC transcript
Appointed director
Inv. presentation
Appointed CFO
PDL BIOPHARMA, INC. (PDLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/06/2020 8-K Quarterly results
05/07/2020 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Reports 2020 First Quarter Financial Results Provides Update to Asset Monetization Plan Discusses Impact of COVID-19 on Operations and Monetization Plan - Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today - INCLINE VILLAGE, Nev. - PDL BioPharma, Inc. reports financial results for the three months ended March 31, 2020 and provides a business update: In March 2020, the Company announced that its Board of Directors approved a Plan of Complete Liquidation and passed a resolution to seek stockholder approval at its next Annual Meeting of Stockholders to dissolve the Company under Delaware state law in the event the Board concludes that the whole Company sale process is unlikely to maximize the value that can be returned to the stockholders. The Company has not se...",
"Presentation"
03/11/2020 8-K Quarterly results
11/06/2019 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Reports 2019 Third Quarter Financial Results Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets Conference call at 4:30 p.m. Eastern time today INCLINE VILLAGE, Nev. - PDL BioPharma, Inc. reports financial results for the three and nine months ended September 30, 2019: Third Quarter Financial Highlights",
"Presentation",
"Information Sheet"
08/07/2019 8-K Quarterly results
05/09/2019 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Reports 2019 First Quarter Financial Results INCLINE VILLAGE, Nev. – PDL BioPharma, Inc. reports financial results for the three months ended March 31, 2019: First Quarter and Recent Financial Highlights",
"Presentation",
"Information Sheet"
03/14/2019 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Reports 2018 Fourth Quarter and Full Year Financial Results INCLINE VILLAGE, Nev. – PDL BioPharma, Inc. reports financial results for the three and 12 months ended December 31, 2018:",
"Presentation",
"Information Sheet"
11/06/2018 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Reports Third Quarter 2018 Financial Results Announces CEO succession plan INCLINE VILLAGE, Nev. – PDL BioPharma, Inc. reports financial results for the three and nine months ended September 30, 2018 including: Third Quarter Financial Highlights",
"Presentation",
"Information Sheet"
08/08/2018 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Reports Second Quarter 2018 Financial Results INCLINE VILLAGE, NV, – PDL BioPharma, Inc. reports financial results for the three and six months ended June 30, 2018 including: Second Quarter Financial Highlights",
"Presentation",
"Information Sheet"
05/09/2018 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Announces First Quarter 2018 Financial Results",
"Presentation",
"Information Sheet"
03/08/2018 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results Total Revenues Increased by 31% in 2017 GAAP EPS Increased 350% and 82% for Q417 and FY 2017, respectively",
"Presentation",
"Information Sheet"
11/02/2017 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Announces Third Quarter 2017 Financial Results Third Quarter GAAP EPS Increased 75% Total Revenues Increased by 17% and 42% for 3Q17 and YTD 2017, respectively",
"Presentation",
"Information Sheet"
08/03/2017 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Announces Second Quarter 2017 Financial Results Total Revenues Increased by 583% and 52% for 2Q17 and YTD 2017, respectively",
"Presentation",
"Information Sheet"
05/03/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
05/04/2016 8-K Form 8-K - Current report
02/22/2016 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results - Record Annual and Quarterly Revenues Achieved - - Nine Percent Annual EPS Growth -",
"Presentation",
"Information Sheet"
11/04/2015 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Announces Third Quarter 2015 Financial Results",
"Presentation",
"Information Sheet"
08/05/2015 8-K Investor presentation, Quarterly results
Docs: "PDL BioPharma Announces Second Quarter 2015 Financial Results",
"Presentation",
"Information Sheet"
05/06/2015 8-K Quarterly results
Docs: "PDL BioPharma Announces First Quarter 2015 Financial Results -Net Income Increased 16 percent-",
"Presentation",
"Information Sheet"
02/23/2015 8-K Quarterly results
Docs: "PDL BioPharma Announces Fourth Quarter and Full Year 2014 Financial Results -Annual Revenues Increased 27 percent During 2014-",
"Presentation",
"Information Sheet"
11/10/2014 8-K Quarterly results
Docs: "PDL BioPharma Announces Third Quarter 2014 and Year to Date Financial Results -Third Quarter Revenues Increased 64 Percent-",
"Presentation",
"Information Sheet"
08/18/2014 8-K Quarterly results
Docs: "PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results -Revenues Increased 23 Percent Year to Date-"
05/12/2014 8-K Quarterly results
Docs: "PDL BioPharma Announces First Quarter 2014 Financial Results -Revenues Increased 52 Percent-",
"Presentation",
"Information Sheet"
03/03/2014 8-K Quarterly results
Docs: "PDL BioPharma Announces Fourth Quarter and Full Year 2013 Financial Results -Annual Revenues Increased 18 percent during 2013-",
"Presentation",
"Information Sheet"
11/06/2013 8-K Form 8-K - Current report
08/08/2013 8-K Quarterly results
Docs: "PDL BioPharma Announces Second Quarter 2013 Financial Results",
"PDL BioPharma, Inc. Following are some of the key points regarding PDL’s second quarter 2013 financial and business results. Net Income ● Net income for the second quarter of 2013 was $93.7 million, or $0.62 per diluted share, as compared with net income of $73.5 million, or $0.52 per diluted share, in the same quarter of 2012. The increase in net income in the second quarter is primarily due to the 14 percent increase in royalty revenues and the release of a tax liability of $5.7 million, which reduced the effective tax rate for the quarter. 2013 Dividends ● On June 12, 2013, PDL paid its second quarterly dividend in 2013 to stockholders of record, totaling $21 million and using earnings generated in the second quarter of 2013. The Board of Directors previously declared two re..."
05/09/2013 8-K Quarterly results
Docs: "PDL BioPharma Announces First Quarter 2013 Financial Results",
"Net Income"
03/01/2013 8-K Form 8-K - Current report
11/05/2012 8-K Form 8-K - Current report
08/02/2012 8-K Form 8-K - Current report
05/03/2012 8-K Form 8-K - Current report
02/23/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy